Stanford researchers developed and patented a multiplexed immunohistochemistry method called multiplexed ion beam imaging (MIBI), which uses antibodies tagged with non-biological elemental isotopes (e.g. rare earth elements) and secondary ion mass spectroscopy.
Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.
Stanford researchers have developed an improved method of distinguishing live and dead cells using mass cytometry, a next-generation form of flow cytometry.
High-grade serous ovarian cancer (HG-SOC) is the most lethal gynecologic malignancy, in large part because most patients present with late-stage disease and receive the same therapeutic regimen despite significant heterogeneity in disease and clinical response.
A team of Stanford researchers has identified mutations in the LNK gene in a subset of patients with chronic myeloproliferative neoplasms (MPNs). LNK (also known as SH2B3) is an adaptor protein that inhibits JAK-STAT signaling.
GateFinder is a flexible, automated, objective algorithm that quickly analyzes complex mass cytometry datasets to identify simple signatures (“gates”) for FACS (fluorescent automated cell sorting) purification.
Stanford researchers have developed a versatile computational approach for easily visualizing and analyzing multidimensional molecular data, such as flow cytometry data.
The Nolan laboratory has created second-generation retrovirus producer lines, termed Phoenix, for the generation of helper free ecotropic and amphotropic retroviruses.
The FELIX vector system, like the PHOENIX MLV-based packaging system, produces high-titre retroviral particles capable of stably transducing a wide variety of target cells with a gene of interest.
293T is a human cell line that has unique properties useful in many applications, including those requiring efficient transfection, gene expression, DNA replication, or viral production.
Rapid, Stable, High titre production of Recombinant Retrovirus
This method of rapid production of high titre retrovirus for large scale production involves a retrovirus construct with an Epstein Barr Virus origin of replication and EBNA protein.